What is HC Wainwright’s Forecast for NAGE Q4 Earnings?

Niagen Bioscience, Inc. (NASDAQ:NAGE) – Research analysts at HC Wainwright issued their Q4 2025 EPS estimates for shares of Niagen Bioscience in a note issued to investors on Tuesday, February 17th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of $0.02 per share for the quarter. HC Wainwright also issued estimates for Niagen Bioscience’s Q2 2026 earnings at $0.09 EPS and Q4 2026 earnings at $0.13 EPS.

A number of other equities analysts also recently commented on NAGE. Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a report on Thursday, January 22nd. Canaccord Genuity Group cut their price target on shares of Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $14.28.

Niagen Bioscience Trading Down 1.6%

Shares of Niagen Bioscience stock opened at $4.86 on Thursday. The business’s fifty day moving average price is $6.03 and its 200 day moving average price is $7.47. Niagen Bioscience has a twelve month low of $4.78 and a twelve month high of $14.69. The stock has a market capitalization of $387.88 million, a P/E ratio of 20.25 and a beta of 2.35.

Institutional Investors Weigh In On Niagen Bioscience

Several hedge funds have recently modified their holdings of NAGE. SG Americas Securities LLC boosted its holdings in Niagen Bioscience by 5.7% in the 4th quarter. SG Americas Securities LLC now owns 54,649 shares of the company’s stock worth $348,000 after acquiring an additional 2,950 shares during the period. Swiss National Bank lifted its position in shares of Niagen Bioscience by 3.0% during the fourth quarter. Swiss National Bank now owns 110,100 shares of the company’s stock worth $700,000 after purchasing an additional 3,200 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Niagen Bioscience by 5.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 60,342 shares of the company’s stock valued at $384,000 after purchasing an additional 3,215 shares during the period. Financial Consulate Inc. acquired a new stake in Niagen Bioscience during the 3rd quarter valued at $33,000. Finally, Wells Fargo & Company MN increased its stake in Niagen Bioscience by 6.9% during the 4th quarter. Wells Fargo & Company MN now owns 58,337 shares of the company’s stock worth $371,000 after buying an additional 3,740 shares during the period. 15.41% of the stock is currently owned by hedge funds and other institutional investors.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.